^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Giant Cell Tumor of Bone

Related cancers:
6d
Benign intra-articular soft tissue tumors mimicking hip septic arthritis: an arthroscopic case series with tenosynovial giant cell tumor predominance. (PubMed, BMC Musculoskelet Disord)
Differentiating benign intra-articular tumors from SAH remains difficult, particularly among younger and female patient populations with acute presentations of TGCT which, as observed in the present study, may be explained by histopathologic evidence of tumor pedicle torsion and resultant necrosis. MRI can be valuable in identifying intra-articular lesions given that clinical and laboratory findings are frequently equivocal. The proposed diagnostic algorithm offers a framework for identifying cases where preoperative MRI may be beneficial, though it requires validation in larger studies.
Journal
|
CRP (C-reactive protein)
8d
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages. (PubMed, Neuro Oncol)
Overall, our findings indicate that PMMRDGs represent a distinct type of IDH-wildtype gliomas with potential for long-term survival likely driven by immune activation.
Journal • Mismatch repair • Tumor mutational burden • dMMR
|
TMB (Tumor Mutational Burden)
|
TMB-H • MSI-H/dMMR • IDH wild-type
8d
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
9d
Clinical significance of immunocyte- and ferroptosis-related markers for the prognosis of patients with tenosynovial giant cell tumor: A cross-sectional study. (PubMed, Cancer Treat Res Commun)
Ferroptosis, immune, and proliferation markers differ significantly between TGCT subtypes and recurrence status. The ACSL4+CD8 signature shows excellent potential for subtype differentiation, while the Ki-67+CSF1R+tumor diameter index is a strong recurrence predictor. These exploratory findings support targeted biomarker use in TGCT management, though external validation in larger, prospective cohorts is required.
Observational data • Journal
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • GPX4 (Glutathione Peroxidase 4) • CSF1R (Colony stimulating factor 1 receptor) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
13d
From bone alterations to tumors: genetic drivers linking Paget's disease of bone to cancer. (PubMed, Crit Rev Oncol Hematol)
A central shared mechanism is the dysregulation of the NFκB pathway, which in PDB leads to increased osteoclast differentiation, and in cancer fosters a pro-inflammatory environment that promotes tumorigenesis. Understanding how altered bone remodelling intersects with cancer‑related signalling highlights shared molecular vulnerabilities that could be exploited therapeutically, and provides a framework for future mechanistic and translational studies in PDB‑associated cancer.
Review • Journal
|
SQSTM1 (Sequestosome 1) • TNFRSF11A (TNF Receptor Superfamily Member 11a) • VCP (Valosin Containing Protein)
15d
Clear Cell Renal Cell Carcinoma With Syncytial Giant Cells: A Case Report With Morphological and Immune-microenvironmental Characterization. (PubMed, Anticancer Res)
SGCs may represent a terminally differentiated tumor cell variant of ccRCC associated with localized TGF-β-related immunosuppressive niche formation, potentially contributing to tumor immune evasion and progression.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • PAX8 (Paired box 8)
15d
TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone (clinicaltrials.gov)
P=N/A, N=70, Recruiting, St. Anne's University Hospital Brno, Czech Republic
New trial
22d
An Aggressive Variant of Central Giant Cell Granuloma of the Posterior Maxilla With Reactive Osteogenesis: A Case Report and Review of the Literature. (PubMed, Cureus)
The case highlights the importance of comprehensive clinicoradiological and histopathological correlation, supplemented by immunohistochemistry, for accurate diagnosis, particularly in atypical presentations. Considering the potential for aggressive behavior and recurrence, appropriate surgical management and long-term follow-up are essential for optimal outcomes.
Journal
|
TP63 (Tumor protein 63)
23d
Disappearance of histone H3F3A mutation in metastatic giant cell tumor of bone during long term follow up. (PubMed, Discov Oncol)
The disappearance of the H3F3A mutation may be associated with malignant transformation in GCTB, whereas our findings suggest that it does not correspond to the tumor's morphological or biological characteristics.
Journal
|
H3-3A (H3.3 Histone A)
24d
Case Report: Identification of rare H3-3A p.G35W variant in a case of adolescent tectal plate low-grade glioma. (PubMed, Front Oncol)
The histone H3 variant (H3-3A p.G35W) detected in our patient has not been previously characterised in tectal plate gliomas, rendering it an unclear predictor of tumour behaviour. In this case study, we discuss the importance of methylation profiling and the potential implications of H3 G34-mutant gliomas.
Journal
|
TP53 (Tumor protein P53) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ATRX (ATRX Chromatin Remodeler) • DAXX (Death-domain associated protein) • H3-3A (H3.3 Histone A)
|
TP53 mutation
24d
Tenosynovial Giant Cell Tumor (TGCT) in the Hip Joint With an APOB Mutation. (PubMed, Case Rep Orthop)
An arthroscopic examination revealed numerous white synovial, chondromate-like tissues under the articular capsule, and D-TGCT was diagnosed based on the histopathological results. One year after the surgery, the patient had good functional recovery and no tumor recurrence.
Journal
|
APOB (Apolipoprotein B)
29d
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)